lunes, 7 de julio de 2014

Bupivacaína liposomal de liberación lenta para analgesia postqurúrgica

Bupivacaína liposomal de liberación lenta para analgesia postqurúrgica 
Liposomal extended-release bupivacaine for postsurgical analgesia.
Lambrechts M, O'Brien MJ, Savoie FH, You Z.
Patient Prefer Adherence. 2013 Sep 6;7:885-90.
Abstract
When physicians consider which analgesia to use postsurgery, the primary goal is to relieve pain with minimal adverse side effects. Bupivacaine, a commonly used analgesic, has been formulated into an aqueous suspension of multivesicular liposomes that provide long-lasting analgesia for up to 72 hours, while avoiding the adverse side effects of opioids. The increased efficacy of liposomal extended-release bupivacaine, compared tobupivacaine hydrochloride, has promoted its usage in a variety of surgeries including hemorrhoidectomy, bunionectomy, inguinal hernia repair, total knee arthroplasty, and augmentation mammoplasty. However, like other bupivacaine formulations, the liposomal extended-release bupivacaine does have some side effects. In this brief review, we provide an update of the current knowledge in the use of bupivacaine for postsurgical analgesia.
KEYWORDS: analgesia; bupivacaine; efficacy; liposome; patient satisfaction; side effects 


Atentamente
Anestesiología y Medicina del Dolor
www.anestesia-dolor.org

Publicar un comentario